CELLDEX THERAPEUTICS INC NEW's ticker is CLDX and the CUSIP is 15117B202. A total of 56 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q3 2019. The put-call ratio across all filers is 0.61 and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2020 | $83,000 | -51.7% | 50,200 | -35.1% | 0.00% | 0.0% |
Q4 2019 | $172,000 | -45.2% | 77,300 | -47.5% | 0.00% | -50.0% |
Q3 2019 | $314,000 | -42.8% | 147,300 | -28.1% | 0.00% | -42.9% |
Q2 2019 | $549,000 | -9.9% | 204,900 | +65.6% | 0.01% | -12.5% |
Q1 2019 | $609,000 | – | 123,700 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Kynam Capital Management, LP | 1,605,390 | $71,552,232 | 10.98% |
Octagon Capital Advisors LP | 761,398 | $33,935,509 | 5.28% |
TSP Capital Management Group, LLC | 269,895 | $12,029,225 | 4.50% |
Redmile Group, LLC | 1,977,451 | $88,134,991 | 3.60% |
COMMODORE CAPITAL LP | 495,823 | $22,099 | 3.33% |
Tri Locum Partners LP | 176,109 | $7,849,000 | 3.18% |
ACUTA CAPITAL PARTNERS, LLC | 115,000 | $5,125,550 | 3.15% |
Ikarian Capital, LLC | 267,476 | $11,921,406 | 2.88% |
RTW INVESTMENTS, LP | 3,084,215 | $137,463,463 | 2.81% |
Eversept Partners, LP | 558,774 | $24,904,557 | 2.18% |